KF
ACOR

Krilogy Financial’s Acorda Therapeutics ACOR Stock Holding History

Krilogy Financial’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-2
Closed -$4K – 858
2017
Q2 		$4K Hold
2
– – ﹤0.01% 625
2017
Q1 		$4K Hold
2
– – ﹤0.01% 607
2016
Q4 		$4K Hold
2
– – ﹤0.01% 607
2016
Q3 		$4K Hold
2
– – ﹤0.01% 627
2016
Q2 		$5K Hold
2
– – ﹤0.01% 611
2016
Q1 		$5K Hold
2
– – ﹤0.01% 543
2015
Q4 		$9K Sell
2
-6
-75% -$26.2K 0.01% 268
2015
Q3 		$24K Buy
+8
New +$31K 0.01% 294

Other funds holding ACOR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Krilogy Financial's ACOR Position: Q3 2017 in Review

Krilogy Financial sold out of Acorda Therapeutics (ACOR) in Q3 2017, closing a stake of 2 shares — an estimated $4K sold.

Krilogy Financial first reported a position in ACOR in Q3 2015 and held it in 8 quarters. The position peaked at $24K in Q3 2015. 152 funds tracked by Wall St. Rank hold ACOR as of Q3 2017.

  • Krilogy Financial reported no remaining Acorda Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Krilogy Financial sold 2 Acorda Therapeutics shares in Q3 2017, an estimated $4K.
  • Krilogy Financial first reported a position in Acorda Therapeutics in Q3 2015 and held it in 8 quarters.
  • Krilogy Financial's Acorda Therapeutics position peaked at $24K in Q3 2015.
  • 152 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q3 2017.

Based on Krilogy Financial's 13F filing for Q3 2017, filed 15 Nov 2017.